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ABBREVIATIONS
MAGE: Melanoma Antigens Genes; CDKs: Cyclin/Cyclin-
Dependent Kinases; AR: Androgen Receptor; E1A: Human 
Adenoviral Early Region Protein E1A; HDM2: Human Double 
Minute 2; HDAC1: Histone Deacetylase 1; RPs: Ribosomal 
Proteins; p75NTR: p75 Neurotrophin Receptor; p75ICD: p75NTR 
Intracellular domain; PML: Promyelocytic Leukemia protein
INTRODUCTION
The first three members of the MAGE family were discovered 
in 1991, as a result of a screening performed to identify tumor 
specific antigens from melanoma cells [1]. Nowadays, MAGE 
family includes more than 50 genes containing a Mage Homology 
Domain (MHD), a highly conserved domain of approximately 200 
amino acids.
MAGE family has been divided in two subfamilies, MAGE-I 
and MAGE-II, according to its tissue pattern expression. MAGE-I 
are tumor specific proteins and its expression in normal adult 
cells is restricted to testis and placenta. These genes are clustered 
in three different regions of the X chromosome, forming the 
MAGE-A, MAGE-B and MAGE-C groups [2]. Conversely, proteins 
belonging to MAGE-II subfamily are widely expressed in many 
embryonic and adult tissues, particularly in the nervous system 
[3], posses a less conserved MHD and their loci are not restricted 
to the X chromosome. MAGE-II proteins include Mage-D1/
NRAGE/Dlxin-1, Mage-D2, MageD3/Trophinin/Magphinin, 
Mage-E1/MageD4, MageE2, Mage-F1, Mage-G1/Necdin-like 2, 
Mage-H1, MageL2 and Necdin. 
Due to their highly conserved protein sequence, MAGE-I 
functions were a priori considered potentially redundant. These 
proteins were, at the beginning, mainly studied as possible 
antigens for cancer vaccines or as diagnostic and prognostic 
markers of cancer [4-6]. Molecular and cell biology studies 
aimed to shed light on their cellular functions arrived some years 
later. Fortunately, during the last decade, several functional 
characterizations of MAGE proteins were performed and their 
interaction and regulation with several transcription factors arise 
as the mechanism underlying their biological functions [7,8].
E2F1 is a member of the E2F family and is among the 
transcription factors reported to be modulated by MAGE proteins. 
E2F1 specifically binds promoters and induces the expression 
of genes involved in G1/S-phase transition. This pathway is 
regulated by pocket proteins such as retinoblastoma protein (Rb), 
p107 and p130, which prevent E2F1 activation by binding to and 
directly blocking the E2F transactivation domain, or by recruiting 
chromatin-modifying proteins (i.e.; histone deacetylases, 
methyltransferases and Polycomb group proteins) to E2F-
binding sites, thereby causing direct gene repression. When 
growth factor signaling activate cyclin/cyclin-dependent kinases 
(CDKs) complexes, pocket proteins became phosphorylated and 
their blocking action on E2F is released. As result, E2F1 is free 
to transactivate a number of target genes associated to cell-cycle 
progression through the S phase. 
Besides, E2F1 is also able to trigger apoptosis under specific 
situations or processes, such as the normal brain development. 
During vertebrate development roughly half of all neurons 
generated die [9,10] and this process ultimately appears to play 
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pre- and postsynaptic elements [11]. This neuron death requires 
the transcription-dependent induction of E2F1 pro-apoptotic 
pathway. 
In this article we will focus on reported cases of E2F1 
modulation by members of MAGE-I and MAGE-II subfamilies and 
the resulting biological consequences observed in normal and 
tumor cells.
MAGE-I proteins as positive regulators of E2F1 
induced proliferation
MageA11 is a co-regulator of Androgen Receptor (AR), a 
ligand-dependent transcriptional factor which has a critical 
role in sexual development as well as tumor formation and 
progression in prostate cancer [12]. It has been recently 
reported that MAGEA11 is able to interact with endogenous 
hypophosphorylated form of E2F1 and cause an increased in 
E2F1 transcriptional activity [13]. Besides, MageA11 is also able 
to interact with members of the pocket protein family as p107 and, 
to a lesser extent, with pRB. Interaction of MAGEA11 with p107 
results in p107 stabilization by inhibition of its ubiquitination. It 
has been suggested that MAGEA11-dependent increase in E2F1 
transcriptional activity is due to MAGEA11/p107 interaction, 
which released transcriptional active E2Fs, similarly to that 
observed with the viral oncogene E1A (human adenoviral early 
region protein E1A) which is able to transform cells by activating 
E2 F1 through competitive interaction with proteins from the Rb 
family. 
Authors also observed that E2F1 strongly associates with 
p107 in prostate cancer cell with endogenous expression of 
MAGEA11, and proposed MAGEA11 expression in prostate 
cancer cells could reverse p107 from a transcriptional repressor 
to a transcriptional activator of E2F1 [13].
More recently, it was reported that tumor suppressor p14ARF 
prevented MAGEA11 interaction with the E2F1, and inhibited the 
MAGEA11-induced increase in E2F1 transcriptional activity [14].
MAGEA11 is targeted for proteasomal degradation by human 
p14ARF, independently of HDM2 E3 ubiquitin ligase or lysine 
ubiquitination. Degradation of MAGEA11 promoted by the human 
p14ARF tumor suppressor contributes to low levels of MAGEA11 in 
nontransformed cells, and higher levels of MAGEA11 associated 
with low levels of p14ARF increases AR and E2F1 transcriptional 
activity and promotes the development of castration-resistant 
prostate cancer [14].
MageB2 is a tumor-specific protein belonging to MAGE-I 
subfamily. This protein is expressed in tumors of diverse origin 
[15] and its expression is related with enhanced cell proliferation. 
Recently, we have reported that MageB2 enhances the activity of 
E2F transcription factors and promotes tumor cell proliferation 
[16].
No physical interaction between MageB2 and E2F1 
was detected by performing in vitro and cellular binding 
assays. However, MageB2 strongly interacts with HDAC1, a 
transcriptional repressor able to complex with and inhibit 
E2F1 activity. Indeed, we observed MageB2 expression strongly 
reduced the amount of HDAC1 associated with the E2F1 complex, 
releasing E2F from such interaction and enhancing its free and 
transcriptionally active fraction. On the contrary to what we 
reported about MageA2-induced apoptosis resistance [17,18,7], 
MageB2-induced proliferation is independent of p53 [16].
When uncontrolled cellular proliferation occurs, cells 
triggers a ribotoxic stress response through regulation of master 
signaling pathways such as those involving E2F, p53, and c-myc 
proteins. Under this condition, specific ribosomal proteins (RPs) 
are released from the nucleoli to the nucleoplasm as a feedback 
loop to limit high translational demand and, consequently, cell 
proliferation. In the nucleus, ribosomal proteins have been found 
to inhibit E2F activity [19].We have reported that under ribotoxic 
stress, MageB2 expression could counteract the negative 
regulation of RPs on E2F, therefore avoiding part of their cell 
cycle-repressive function. As a consequence, MageB2 is capable 
of enhancing cell cycle progression even under stress conditions. 
This could explain, at least in part, the oncogenic potential of 
MageB2 [16].
MAGE-II proteins as negative regulators of E2F1 
proapoptotic role in brain development and cell 
proliferation
As stated before, E2F1 is capable of inducing 
neuronal apoptosis, a physiological process which plays a critical 
role in the normal development of the mammalian brain [11]. 
E2F1 pro-apoptotic activity in brain is linked to p75 neurotrophin 
receptor (p75NTR). In response to ligand binding, p75NTR can 
release its intracellular domain (p75ICD) and induce E2F1 
activity in differentiating retinal neurons [20]. 
Mage-II proteins are expressed in many embryonic and 
adult tissues, particularly in the nervous system [21,22]. Some 
members of MAGE-II subfamily were reported to be key elements 
in neurogenesis, being capable of modulating the pro-apoptotic 
signaling triggered by p75NTR and E2F1.
One of the better characterized MAGE-II proteins involved in 
regulation of brain development is Necdin, which was initially 
isolated from mouse embryonal carcinoma cells differentiated 
into neurons [23]. The mouse necdin gene is predominantly 
expressed in postmitotic neurons [24], and when expressed 
ectopically, it suppresses proliferation [25] and triggers neuronal 
differentiation [26] in different cell lines.
Another MAGE-II protein which plays a role in neurogenesis is 
the necdin homologue MageG1 [27]. Both human genes encoding 
necdin and MAGE-G1 are located in the proximal chromosome 
15q, a region subject to genomic imprinting and implicated in 
various human neurological and mental disorders. 
More recently, it was reported the existence of Mage protein 
in chicken, CMage, which is the only mage gene in this specie and 
shares close homology with the type II MAGE protein family [28]. 
For these three proteins, a common mechanism was proposed 
to explain how they regulate E2F1-dependent apoptosis in 
normal brain development.
Similarly to the E2F repressor Rb; Necdin, MAGE-G1 
and CMage bind to the transactivation domain of the E2F1 
transcription factor, repressed E2F1-dependent transcription 
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and antagonized E2F1-induced apoptosis in neuroblastoma 
cells. In addition, these proteins also interact with intracellular 
domain of p75 neurotrophin receptor (p75NTR). p75NTR can 
sequester Necdin and MageG1 to the cell membrane, preventing 
it interaction with E2F1 and consequently facilitating apoptosis 
in neuroblastoma cells [27-29].
Other MAGE-II proteins as MageD1 and MageH1 have been 
shown to interact with the intracellular domain of p75NTR, but 
their ability to interact and modulate E2F1 activity has not been 
reported [30,31]. 
Besides its role in apoptosis, ectopic expression of necdin 
strongly suppresses the proliferation of tumor-derived cell 
lines [25,28,32]. Necdin, also interacts with E2F1 on the Cdk1 
promoter to repress the transcriptional activation of the Cdk1 
gene [33]. Thus, necdin is likely to downregulate the expression 
of E2F dependent cell cycle-related genes in proliferative cells 
and exerts its anti-mitotic activity during neurogenesis [34].
DISCUSSION AND CONCLUSION
Functional characterization of MAGE proteins points to a 
role in the regulation of transcription through the regulation of 
specific transcription factors, as Skip by MageA1 [35], androgen 
receptor by MageA11 [36-39] and p53 and PML by MageA2 
[18,19,40].
The regulation of E2F1 activity by MAGE proteins was first 
reported for different members of MAGE-II subfamily. First, 
Necdin was reported to regulate cell proliferation and apoptosis 
through direct binding and repression of E2F1 transcriptional 
activity [29]. Later, it was reported that MageG1 [27] and the only 
MAGE protein in chicken, CMage [28] also inhibited the E2F1 
transcription factor through direct association, especially in 
post mitotic neurons, and resulting in E2F1 dependent apoptosis 
inhibition.
More recently, it was reported the regulation of E2F1 by 
specific members of MAGE-I subfamily. For their tissue pattern 
expression, MAGE-I regulation of E2F activity represents a highly 
relevant issue in cancer research. In this respect, it has been 
reported that MageA11 interacts with the pocket protein p107 
and enhances E2F1 activity [13] as part of its pro oncogenic 
activity in prostate cancer. Besides, MageB2 interacts with 
transcriptional repressor HDAC1, weakening its recruitment to 
the E2F1 protein complex and, therefore, increasing the fraction 
of free and active E2F [16].
Concerning E2F1 activity, MAGE-I tumor specific proteins 
seem to play an opposite role of that reported for MAGE-II 
proteins. Meanwhile MAGE-I proteins enhance E2F1 pro-
oncogenic activity, MAGE-II proteins act as E2F1 inhibitors, 
negatively regulating cell proliferation and contributing to 
normal brain development.
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